D-dimer Testing Market Size - By Testing Method (Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immuno-turbidimetric Assays, Fluorescence Immunoassays), By Application, By End-use – Global Forecast to 2032

D-dimer Testing Market Size - By Testing Method (Enzyme-linked Immunosorbent Assay (ELISA), Latex-enhanced Immuno-turbidimetric Assays, Fluorescence Immunoassays), By Application, By End-use – Global Forecast to 2032

D-dimer Testing Market Size

D-Dimer Testing Market size was valued at over USD 1 billion in 2022 and is projected to reach more than USD 2 billion by 2032. D-dimer testing is a laboratory test used to detect the presence of D-dimer in the blood. D-dimer is a small protein fragment that is produced when a blood clot is dissolved in the body. It is considered a fibrin degradation product.
 

Additionally, the growing prevalence of blood clotting related genetic disorders is accelerating market growth. Genetic disorders that increase the risk of blood clot formation are uncommon but can have serious health implications. For instance, protein C and protein S deficiencies are rare, with estimated frequencies of around 1 in 300 to 500 individuals for protein C deficiency and 1 in 20,000 to 25,000 individuals for protein S deficiency.
 

Moreover, increasing demand for next-generation point-of-care (POC) D-dimer tests. POC D-dimer tests enable healthcare providers to immediately rule out or confirm the presence of a thrombotic event, guiding further diagnostic evaluations or treatment plans. Rapid decision-making can lead to more efficient patient management, potentially reducing unnecessary imaging procedures, hospital admissions, and associated costs, thereby augmenting market expansion.

COVID-19 Impact

The COVID-19 epidemic had a positive impact on the d-dimer testing market. COVID-19 is associated with an increased risk of blood clotting and thrombotic complications. D-dimer testing plays a crucial role in evaluating and monitoring coagulation abnormalities in COVID-19 patients. As a result, there has been a surge in the utilization of D-dimer testing during the pandemic. COVID-19 can increase the risk of thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). D-dimer testing is instrumental in the diagnosis and management of these complications, assisting in ruling out or confirming the presence of blood clots. Therefore, COVID-19 pandemic accelerated the market growth.
 

D-dimer Testing Market Trends

Technological advancements regarding D-dimer testing are anticipated to stimulate market progression. Immunoassay techniques, such as enzyme-linked immunosorbent assay (ELISA), have been widely used in D-dimer testing. Advances in immunoassay technology have led to the development of overly sensitive and specific assays for detecting D-dimer levels in blood samples. Moreover, integration of D-dimer testing with digital platforms and electronic medical records has facilitated seamless data management, result interpretation, and communication between healthcare professionals. This digitization improves workflow efficiency and enables remote monitoring and consultation.
 

D-dimer Testing Market Analysis

Based on testing method, the d-dimer testing market is segmented into enzyme-linked immunosorbent assay (ELISA), latex-enhanced immuno-turbidimetric assays, fluorescence immunoassays, and others. The enzyme-linked immunosorbent assay (ELISA) segment held the largest revenue size over USD 460 million in 2022 and is estimated to witness significant growth more than USD 700 million by 2032. ELISA assays for D-dimer testing are highly sensitive, capable of detecting even low levels of D-dimer in blood samples. This sensitivity allows for the accurate identification of thrombotic events and helps in ruling out or confirming the presence of blood clots. Furthermore, an increase in the availability of testing method coupled with several other businesses working towards creating innovative technology will support the segment's revenue.
 

D-dimer testing market is bifurcated based on the application including deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), others. The deep vein thrombosis (DVT) segment is anticipated to grow over USD 770 million by 2032. DVT is a widespread medical condition that frequently remains untreated and mostly affects hospitalized patients due to immobility. Due to this, DVT is more common, and its accompanying consequences are more likely to occur. In the U.S., venous thrombosis affects more than 200,000 people annually, per research studies. Therefore, increasing prevalence of deep vein thrombosis (DVT) is anticipated to boost d-dimer testing adoption.
 

The d-dimer testing market is segmented by end-use into hospitals, diagnostic centers, research institutes, and others. Diagnostic centers segment held a significant share in the global market accounting for more than 29% business share in 2022 and is estimated to witness significant revenue over USD 600 million by 2032. The diagnostic centers segment is anticipated to hold high growth potential during the analysis period. Due to the widespread availability of innovative and affordable treatments, factors including the increase in laboratory testing and growing preference for diagnostics laboratories will fuel market expansion. These facilities also offer early and precise disease diagnosis and patient treatment, which is anticipated to accelerate segment expansion.
 

U.S. d-dimer testing market accounted for more than USD 450 billion in 2022 and will grow momentously more than USD 615 billion by 2032. The affordability of d-dimer testing among the target population base and ongoing technological developments are primarily responsible for the market growth. Further, the region's high healthcare spending on health care management and rising disposable income will spur the North America market forecasts. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S. hence, the potential for market expansion will stimulate over the coming years.
 

D-dimer Testing Market Share

Some of the notable key industry players operating in the d-dimer testing market include

• Abbott Laboratories
• BioMedica Diagnostics
• biomérieux SA
• Diazyme Laboratories Inc. (General Atomics)
• FHoffmann-La Roche Ltd.
• HORIBA Ltd.
• Quidel Corporation
• Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.)
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.
• Unbound Medicine Inc
• Werfen

These market participants are implementing various growth strategies such as collaborations, partnerships, acquisitions & mergers, and new product development and launches to strengthen testing method offerings as well as gain a competitive edge over others.
 

D-dimer Testing Industry News 

• In April 2019, in collaboration with Diazyme Laboratories, Inc., Ortho Clinical Diagnostics, a company with headquarters in the U.S., launched their D-Dimer assay. This new test is a part of Ortho Clinical's MicroTip Partnership Assay Programme, which enables the business to offer high-quality, adaptable, rapid, and specialised testing options. This product introduction increased the business's capacity to provide customers with innovative assay.
   

D-dimer testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Testing Method (USD Million)

• Enzyme-linked immunosorbent assay (ELISA)
• Latex-enhanced immuno-turbidimetric assays
• Fluorescence immunoassays
• Others

By Application (USD Million)

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Disseminated intravascular coagulation (DIC)
• Others

By End-use (USD Million)

• Hospitals
• Diagnostic centers
• Research institutes
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Poland
  • Switzerland
  • Norway
  • Finland
  • Sweden
  • Denmark
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Taiwan
  • Indonesia
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Israel